These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32206324)

  • 41. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
    Shapiro MS; Abrams Z; Lieberman N
    Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study.
    Ohkura T; Inoue K; Fujioka Y; Nakanishi R; Shiochi H; Sumi K; Yamamoto N; Matsuzawa K; Izawa S; Ohkura H; Kato M; Yamamoto K; Taniguchi S
    BMC Res Notes; 2013 Nov; 6():453. PubMed ID: 24215809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
    Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
    Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes.
    Landgraf R; Frank M; Bauer C; Dieken ML
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S38-44. PubMed ID: 11063283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes.
    Komatsu H; Enomoto M; Shiraishi H; Morita Y; Hashimoto D; Nakayama S; Funakoshi S; Hirano S; Terada Y; Miyamura M; Fujimoto S
    Diabetol Int; 2020 Oct; 11(4):388-392. PubMed ID: 33088647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
    Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus.
    Kawamori R; Kaku K; Hanafusa T; Kashiwabara D; Kageyama S; Hotta N
    J Diabetes Investig; 2012 Jun; 3(3):302-8. PubMed ID: 24843581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma.
    Bergmann TK; Filppula AM; Launiainen T; Nielsen F; Backman J; Brosen K
    Br J Clin Pharmacol; 2016 Feb; 81(2):313-5. PubMed ID: 26446447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Diabetes Res Clin Pract; 2003 Jun; 60(3):161-9. PubMed ID: 12757988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insulin and oral agents for managing cystic fibrosis-related diabetes.
    Onady GM; Stolfi A
    Cochrane Database Syst Rev; 2016 Apr; 4():CD004730. PubMed ID: 27087121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
    Niemi M; Kajosaari LI; Neuvonen M; Backman JT; Neuvonen PJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):441-7. PubMed ID: 15025742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
    Tornio A; Niemi M; Neuvonen M; Laitila J; Kalliokoski A; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2008 Sep; 84(3):403-11. PubMed ID: 18388877
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.
    Yoshihara T; Kumashiro N; Kanazawa Y; Mita T; Sakurai Y; Kawai J; Abe M; Motojima K; Hara K; Yamazaki Y; Kanazawa A; Miwa S; Sato F; Kanno R; Shimizu T; Sakai K; Uchino H; Watada H; Tanaka Y; Kawamori R; Hirose T
    Endocr J; 2006 Feb; 53(1):67-72. PubMed ID: 16543674
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
    Rizzo MR; Barbieri M; Grella R; Passariello N; Paolisso G
    Diabetes Metab; 2005 Jun; 31(3 Pt 1):255-60. PubMed ID: 16142016
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin.
    Murakami T; Nambu T; Kato T; Matsuda Y; Yonemitsu S; Muro S; Oki S
    Tohoku J Exp Med; 2015 Apr; 235(4):255-60. PubMed ID: 25810423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of Glycemic Excursion in Patients with New Onset Type 2 Diabetes Mellitus before and after Treatment with Repaglinide.
    Hezarkhani S; Bonakdaran S; Rajabian R; Shahini N; Marjani A
    Open Biochem J; 2013; 7():19-23. PubMed ID: 23526382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin and oral agents for managing cystic fibrosis-related diabetes.
    Onady GM; Stolfi A
    Cochrane Database Syst Rev; 2013 Jul; (7):CD004730. PubMed ID: 23893261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.